We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TTP and ODx to Develop New Technology Addressing Antibiotic Resistance
Product News

TTP and ODx to Develop New Technology Addressing Antibiotic Resistance

TTP and ODx to Develop New Technology Addressing Antibiotic Resistance
Product News

TTP and ODx to Develop New Technology Addressing Antibiotic Resistance


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "TTP and ODx to Develop New Technology Addressing Antibiotic Resistance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TTP plc (TTP), an independent technology and product development company, has announced today that it has partnered with ODx (ODx Innovations Ltd), a company committed to developing a system for assessing urinary tract infections (UTIs). The collaboration is focused on bringing ODx’ system to market through TTP’s Desktop Biology service.

The ODx system offers the potential to revolutionize the turnaround time for the assessment of suspected UTIs, reduce the use of antibiotics and provider faster access to optimal antimicrobial therapy.

ODx’ proprietary detection technique relies on subjecting urine samples to an antibiotic panel to assess the effectiveness of each compound at killing bacteria. TTP and ODx have further refined and developed this technology to provide rapid and multiplexed analysis.  The test passes light through samples, monitoring optical response over time to investigate bacterial growth, and if/how this is affected by the presence of different antibiotics. The multiplex cartridge allows for different antibiotic panels and concentrations to be tested, depending upon clinical settings and geography.

Once released, it is expected the system will be placed in doctors’ offices, hospital outpatient clinics and potentially pharmacies. This will help assess suspected UTIs at the point of care, ensuring the most appropriate antibiotics are identified as quickly as possible. Facilitating the development of personalized treatment plans, the system will help tackle antibiotic resistance by reducing un-necessary prescriptions, whilst making sure that antibiotic courses have the maximum possible effectiveness for a given patient.

The system is being co-developed through TTP’s Desktop Biology service, which was launched in 2016 to help companies accelerate the development of their assay to a product for use in diagnostics or research. TTP has been ODx’ development partner since early 2019, enabling their detection technology through a multi skilled team from both parties covering biology, microfluidics, optics, human factors and engineering capabilities.

Advertisement